High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes

被引:40
作者
Katsuki, H
Hamada, A
Nakamura, C
Arimori, K
Nakano, M
机构
[1] Kumamoto Univ Hosp, Dept Pharm, Kumamoto 8608556, Japan
[2] Miyazaki Med Coll Hosp, Dept Pharm, Miyazaki 8891692, Japan
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 757卷 / 01期
关键词
enantiomer separation; lansoprazole; 5-hydroxylansoprazole; lansoprazole sulfone;
D O I
10.1016/S0378-4347(01)00135-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In this study, a simple, sensitive and enantioselective HPLC method was developed for the simultaneous determination of lansoprazole enantiomers: a proton pump inhibitor, and its major metabolites: 5-hydroxylansoprazole and lansoprazole sulfone in human liver microsomes. After extraction from the microsomal incubation mixture with a diethyl etherdichloromethane (7:3, v/v) mixture, analytes were measured by reversed-phase HPLC on a Chiralcel(R) OD-R column. Detection was made using an ultraviolet absorbance detector set at a wavelength of 285 nm. The mobile phase consisted of a methanol-water (75:25, v/v) mixture. At a flow-rate of 0.5 ml/min, the total run time was 35 min. The limit of quantification for both lansoprazole enantiomers was 0.25 muM and for the metabolites 0.13 muM. The method is suitable for the analysis of lansoprazole enantiomers and its metabolites from human microsomal liver incubations. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:127 / 133
页数:7
相关论文
共 17 条
[1]  
AOKI I, 1990, J CHROMATOGR, V571, P583
[2]   LANSOPRAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND ITS THERAPEUTIC EFFICACY IN ACID-RELATED DISORDERS [J].
BARRADELL, LB ;
FAULDS, D ;
MCTAVISH, D .
DRUGS, 1992, 44 (02) :225-250
[3]   Separation of lansoprazole enantiomers in human serum by HPLC [J].
Borner, K ;
Borner, E ;
Lode, H .
CHROMATOGRAPHIA, 1998, 47 (3-4) :171-175
[4]   ANTIPYRINE METABOLISM IN CULTURED RAT HEPATOCYTES [J].
CHENERY, RJ ;
OLDHAM, HG ;
STANDRING, P ;
NORMAN, SJ ;
JENNINGS, P ;
MASON, PA .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (18) :3077-3081
[5]  
DONG SR, 1997, CLIN PHARMACOL THER, V61, P574
[7]   EFFECTS OF A PROTON PUMP INHIBITOR, AG-1749 (LANSOPRAZOLE), ON REFLUX ESOPHAGITIS AND EXPERIMENTAL ULCERS IN RATS [J].
INATOMI, N ;
NAGAYA, H ;
TAKAMI, K ;
SHINO, A ;
SATOH, H .
JAPANESE JOURNAL OF PHARMACOLOGY, 1991, 55 (04) :437-451
[8]   Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans [J].
Katsuki, H ;
Yagi, H ;
Arimori, K ;
Nakamura, C ;
Nakano, M ;
Katafuchi, S ;
Fujioka, Y ;
Fujiyama, S .
PHARMACEUTICAL RESEARCH, 1996, 13 (04) :611-615
[9]   Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects [J].
Katsuki, H ;
Nakamura, C ;
Arimori, K ;
Fujiyama, S ;
Nakano, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) :391-396
[10]  
NAGAYA H, 1990, J PHARMACOL EXP THER, V252, P1289